Ignite Creation Date:
2024-05-06 @ 7:22 PM
Last Modification Date:
2024-10-26 @ 3:05 PM
Study NCT ID:
NCT05985109
Status:
RECRUITING
Last Update Posted:
2023-10-26
First Post:
2023-08-02
Brief Title:
KN 046 Plus Regorafenib in MSS Metastatic Colorectal Cancer
Sponsor:
Peking University Cancer Hospital Institute
Organization:
Peking University Cancer Hospital Institute
Study Overview
Official Title:
A Phase II Multi-cohort Clinical Study Evaluating The Efficacy and Safety of KN046 in Combination With Regorafenib for Metastatic Microsatellite-Stable Colorectal Cancer a Phase II Multi-cohort Study
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study is an interventional Phase II clinical trial aiming to optimize immunotherapy strategies for microsatellite-stable colorectal cancer We will include three types of metastatic colorectal cancer patients those without liver metastasis or carrying BRAF V600E mutation or unable to tolerate chemotherapy as their initial or second-line treatment The participants will receive a combination treatment of regorafenib and KN046 which is a PD-L1CTLA-4 bispecific antibody Treatment efficacy and safety profile would be evaluated in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None